Solventum Corporation logo

Solventum Corporation

SOLV

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$89.57

+$0.96 · +1.08%

Aug 21, 4:00 PM ET

SOLV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

100

Deep Value

Momentum

42

Neutral

Sentiment

61

Bullish

Risk resilience

71

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Bryan C. Hanson
Listed since
Apr 1, 2024
Employees
20,584

Market position

Day range

Current $89.57

52-week range

Current $89.57

Open
$88.26
Previous close
$88.61
Volume
730.81K
0.48× average
Average volume
1.53M
Average daily volume
Market cap
15.51B USD
Beta
0.67
Market reference 1
50-day average
$80.976
+10.61% above average
200-day average
$76.4198
+17.21% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
10.9×
P/B (TTM)
3.24×
P/S (TTM)
1.87×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.69%
Operating margin
24.99%
Net margin
17.26%

Financial health

Debt / equity
1.1×

Earnings

EPS beat rate
100%
10 beats, 0 misses, 0 met estimates
Average EPS surprise
+12.85%
10 comparable reports
Latest EPS result
2.55
Estimate 1.9 · Beat by 34.21%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.662.141.621.1Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 1.41, estimate 1.31, surprise +7.63%, Beat. Q2 2025, reported May 8, 2025: actual 1.34, estimate 1.21, surprise +10.74%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.69, estimate 1.45, surprise +16.55%, Beat. Q4 2025, reported Nov 6, 2025: actual 1.5, estimate 1.43, surprise +4.90%, Beat. Q1 2026, reported Feb 26, 2026: actual 1.57, estimate 1.5, surprise +4.67%, Beat. Q2 2026, reported May 5, 2026: actual 1.48, estimate 1.35, surprise +9.63%, Beat. Q3 2026, reported Aug 5, 2026: actual 2.55, estimate 1.9, surprise +34.21%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.35, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.3B2.15B2B1.85BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 2.07B USD, estimate 2.05B USD, surprise +1.13%, Beat. Q2 2025, reported May 8, 2025: actual 2.07B USD, estimate 2.02B USD, surprise +2.66%, Beat. Q3 2025, reported Aug 7, 2025: actual 2.16B USD, estimate 2.12B USD, surprise +1.97%, Beat. Q4 2025, reported Nov 6, 2025: actual 2.1B USD, estimate 2.06B USD, surprise +1.96%, Beat. Q1 2026, reported Feb 26, 2026: actual 2B USD, estimate 1.96B USD, surprise +1.84%, Beat. Q2 2026, reported May 5, 2026: actual 2.01B USD, estimate 1.97B USD, surprise +2.01%, Beat. Q3 2026, reported Aug 5, 2026: actual 2.21B USD, estimate 2.15B USD, surprise +2.55%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.93B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$91.22

1.84% upside
Past 12 months12-month forecastHigh $113Average $91.22Low $43.00

Recent analyst actions

12 institutions
WedbushmaintainOutperform

SOLV news

SOLV peers

Continue in GoAI

Research SOLV

research.disclaimer